Nektar Quiets Partnering Talk, Will Keep Oncology Drug For Itself
This article was originally published in The Pink Sheet Daily
Executive Summary
Auspicious data from a pair of Phase II studies has prompted the company to cease partnership discussions - and reassess its priorities.
You may also be interested in...
Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own
Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.
Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own
Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.
Nektar/Bayer Agree To Develop Inhaled Amikacin For Hospital-Acquired Pneumonia
Product combining Nektar’s deep-lung delivery technology and amikacin formulation could reach market in 2010-2011 timeframe, Nektar COO tells “The Pink Sheet” DAILY.